2. Academic Validation
  3. PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth

PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth

  • Nature. 2017 Jun 22;546(7659):554-558. doi: 10.1038/nature22965.
Shafi Kuchay 1 2 3,  Carlotta Giorgi 1 2 4,  Daniele Simoneschi 1 2,  Julia Pagan 1 2 3,  Sonia Missiroli 4,  Anita Saraf 5,  Laurence Florens 5,  Michael P Washburn 5 6,  Ana Collazo-Lorduy 7 8,  Mireia Castillo-Martin 7 9,  Carlos Cordon-Cardo 7,  Said M Sebti 10,  Paolo Pinton 4,  Michele Pagano 1 2 3
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, 522 First Avenue, SRB 1107, New York, New York 10016, USA.
  • 2 NYU Perlmutter Cancer Center, New York University School of Medicine, 522 First Avenue, SRB 1107, New York, New York 10016, USA.
  • 3 Howard Hughes Medical Institute, New York University School of Medicine, 522 First Avenue, SRB 1107, New York, New York 10016, USA.
  • 4 Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
  • 5 The Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.
  • 6 Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA.
  • 7 Department of Pathology at Icahn School of Medicine at Mount Sinai, New York, New York 10029 USA.
  • 8 Spanish Society of Medical Oncology, Madrid, Spain.
  • 9 Department of Pathology at Champalimaud Centre for the Unknown, Lisbon, Portugal.
  • 10 Drug Discovery Department, Moffitt Cancer Center, and Department of Oncologic Sciences, University of South Florida, Tampa, Florida 33612, USA.
PMID: 28614300 DOI: 10.1038/nature22965
Abstract

In response to environmental cues that promote IP3 (inositol 1,4,5-trisphosphate) generation, IP3 receptors (IP3Rs) located on the endoplasmic reticulum allow the 'quasisynaptical' feeding of calcium to the mitochondria to promote oxidative phosphorylation. However, persistent Ca2+ release results in mitochondrial Ca2+ overload and consequent Apoptosis. Among the three mammalian IP3Rs, IP3R3 appears to be the major player in Ca2+-dependent Apoptosis. Here we show that the F-box protein FBXL2 (the receptor subunit of one of 69 human SCF (SKP1, CUL1, F-box protein) ubiquitin ligase complexes) binds IP3R3 and targets it for ubiquitin-, p97- and proteasome-mediated degradation to limit Ca2+ influx into mitochondria. FBXL2-knockdown cells and FBXL2-insensitive IP3R3 mutant knock-in clones display increased cytosolic Ca2+ release from the endoplasmic reticulum and sensitization to Ca2+-dependent apoptotic stimuli. The Phosphatase and tensin homologue (PTEN) gene is frequently mutated or lost in human tumours and syndromes that predispose individuals to Cancer. We found that PTEN competes with FBXL2 for IP3R3 binding, and the FBXL2-dependent degradation of IP3R3 is accelerated in PTEN-/- mouse embryonic fibroblasts and PTEN-null Cancer cells. Reconstitution of PTEN-null cells with either wild-type PTEN or a catalytically dead mutant stabilizes IP3R3 and induces persistent Ca2+ mobilization and Apoptosis. IP3R3 and PTEN protein levels directly correlate in human prostate Cancer. Both in Cell Culture and xenograft models, a non-degradable IP3R3 mutant sensitizes tumour cells with low or no PTEN expression to photodynamic therapy, which is based on the ability of photosensitizer drugs to cause Ca2+-dependent cytotoxicity after irradiation with visible LIGHT. Similarly, disruption of FBXL2 localization with GGTi-2418, a geranylgeranyl transferase inhibitor, sensitizes xenotransplanted tumours to photodynamic therapy. In summary, we identify a novel molecular mechanism that limits mitochondrial Ca2+ overload to prevent cell death. Notably, we provide proof-of-principle that inhibiting IP3R3 degradation in PTEN-deregulated cancers represents a valid therapeutic strategy.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z